Real-life treatment of acute exacerbation of chronic bronchitis-moxifloxacin compared to macrolides
Abstract number: p1055
Schaberg T., Möller M., File T., Stauch K., Landen H.
To compare real-life treatment of acute exacerbation of chronic bronchitis (AECB) using moxifloxacin (MXF) tablets or different p.o. macrolides (MCLs) in terms of symptom relief, time until improvement/cure and overall efficacy and tolerability.
This prospective, non-interventional multicentre study included outpatients with a diagnosis of AECB and a MCL therapy of their last AECB. The current AECB was either treated with MFX tablets or a MCL p.o. The decision about the drug prescribed as well as the dose and duration of therapy was up to the attending physician. Documentation comprised patient characteristics, disease and treatment history, the course of the current AECB treated with MFX or MCL as well as a final assessment of efficacy and tolerability.
In total 1750 patients were included in the analysis, 904 patients were treated with MXF and 846 with a MCL [42.6% clarithromycin (CCR), 31.2% roxithromycin (ROX), 26.2% azithromycin (AZM)]. Patient characteristics did not differ markedly between the two treatment groups (MXF: mean age of 57.4 years, mean BMI of 26.6 kg/m2, 27.7% current smokers; MCL: mean age 56.4 years, mean BMI 26.7 kg/m2, 29.8% current smokers). About 70% of patients had at least one concomitant disease, mostly cardiovascular (MXF group 50.9%, MCL group 45.4%). About 40% of patients in both groups suffered from chronic bronchitis for 1 to 5 years, about 27% for > 5 to 10 years. The mean number of AECBs in the last 12 months was 2.7 and 2.6, respectively. In most MXF patients treatment was applied for 5 (43.8%) or 7 days (42.4%). Main therapy regimens in MCL patients: CCR 500 mg for 47 days, ROX 300 mg for 67 days, AZM 500 mg for 3 days. Symptom relief in both groups at last follow-up is shown in the figure. Mean duration until overall improvement and cure of AECB was 3.2 days (SD 1.5) and 6.2 days (SD 2.6) in MXF patients compared to 4.4 days (SD 1.8) and 7.5 days (SD 3.0) in MCL patients. 8 MXF patients (0.9%) showed no improvement at all vs. 37 MCL patients (4.4%). 19 MXF patients (2.1%) vs. 86 MCL patients (10.2%) had no recovery. Physicians assessed overall efficacy/tolerability as very good or good in 96.1%/98.1% of MXF patients and 67.5%/91.7% of MCL patients. Both treatment groups showed a similar good safety.
These results of AECB therapy under real-life treatment conditions confirm the superiority of moxifloxacin versus macrolides with a faster symptom relief and higher recovery rates.
|Session name:||XXIst ISTH Congress|
|Back to top|